KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
0.9000
+0.0013 (0.14%)
Aug 19, 2026, 4:00 PM EDT - Market closed
KALA BIO Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | - | 3.89 | 11.24 | |
Revenue Growth | - | - | - | - | -65.37% | 76.67% |
Cost of Revenue | - | - | - | - | 2.56 | 4.1 |
Gross Profit | - | - | - | - | 1.33 | 7.14 |
Selling, General & Admin | 17.8 | 23.63 | 18.34 | 20.57 | 65.04 | 105.06 |
Research & Development | 6.61 | 18.78 | 22.09 | 18.59 | 17.65 | 11.52 |
Operating Expenses | 24.41 | 42.41 | 40.43 | 39.15 | 82.69 | 116.58 |
Operating Income | -24.41 | -42.41 | -40.43 | -39.15 | -81.36 | -109.43 |
Interest Expense | -1.1 | -3.28 | -5.78 | -5.81 | -7.27 | -8.38 |
Interest & Investment Income | 0.48 | 1.14 | 2.06 | 2.71 | 0.66 | 0.1 |
Other Non Operating Income (Expenses) | 2.88 | 5.67 | 6.2 | 3.97 | -0.93 | - |
EBT Excluding Unusual Items | -22.15 | -38.87 | -37.96 | -38.29 | -88.88 | -117.71 |
Gain (Loss) on Sale of Assets | -0.55 | -0.55 | - | 4.2 | 47 | - |
Asset Writedown | -1.41 | -1.41 | - | -7.6 | - | - |
Other Unusual Items | 14.03 | 13.85 | -0.55 | -0.51 | -2.93 | 1.72 |
Pretax Income | -10.08 | -26.98 | -38.51 | -42.2 | -44.82 | -142.61 |
Net Income | -10.08 | -26.98 | -38.51 | -42.2 | -44.82 | -142.61 |
Net Income to Common | -10.08 | -26.98 | -38.51 | -42.2 | -44.82 | -142.61 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 8 | 0 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 8 | 0 | 0 | 0 | 0 | 0 |
Shares Change | 6874.92% | 114.65% | 56.09% | 59.94% | 15.50% | 25.67% |
EPS (Basic) | -1.30 | -165.56 | -507.25 | -867.58 | -1473.83 | -5416.07 |
EPS (Diluted) | -1.30 | -165.56 | -507.25 | -867.58 | -1474.00 | -5416.07 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -19.88 | -32.01 | -29.59 | -28.54 | -79.22 | -109.12 |
Free Cash Flow Per Share | -2.57 | -196.40 | -389.75 | -586.70 | -2604.93 | -4144.36 |
Gross Margin | - | - | - | - | 34.22% | 63.55% |
Operating Margin | - | - | - | - | -2090.34% | -973.60% |
Profit Margin | - | - | - | - | -1151.64% | -1268.73% |
Free Cash Flow Margin | - | - | - | - | -2035.48% | -970.83% |
EBITDA | -24.07 | -42.09 | -40.18 | -38.85 | -80.82 | -108.46 |
D&A For EBITDA | 0.34 | 0.32 | 0.26 | 0.3 | 0.54 | 0.98 |
EBIT | -24.41 | -42.41 | -40.43 | -39.15 | -81.36 | -109.43 |